Coherus BioSciences Inc.
www.coherus.com
Latest From Coherus BioSciences Inc.
Amgen's US Biosimilar Launches Are Off To A Steady Start, With A Big Coverage Decision
United HealthCare agreed to cover Mvasi and Kanjinti in a preferred position. Amgen VP-oncology sales & marketing Susan Logan talked to Scrip about the company's first US biosimilar launches.
Advances On the Biosimilar Litigation Battlefield
A look at the evolution of litigation, from Amgen's 'bold' at-risk launch of Herceptin and Avastin biosimilars to the jump in settlements, new battles over manufacturing information and an expected petition to the Supreme Court.
Coherus Set Sights On Taking Fifth Of US Pegfilgrastim Market
Having made a strong start with sales of over $120m in its first six months on the market, Coherus believes its Udenyca biosimilar could end 2019 with more than a fifth of the US pegfilgrastim market by volume.
Amgen’s Nonconformist Position On Biosimilar Payment Policy Reflects Market Strategy
Company objects to legislative proposals that would enhance Medicare Part B reimbursement for biosimilars to boost uptake, even as it launches its first biosimilars in the US market.
Company Information
- Industry
-
Biotechnology
- Large Molecule
-
Pharmaceuticals
- Generic Drugs
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Dermatology
- Gastrointestinal
- Immune Disorders
- Musculoskeletal & Connective Tissue Disorders
- Ophthalmic
- Alias(es)
- BioGenerics Inc.
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Coherus BioSciences Inc.
- Senior Management
-
Dennis Lanfear, Chmn., Pres. & CEO
Jean-Frederic Viret, PhD, CFO
Vladimir Vexler, PhD, CSO
Darlene Horton, MD, CMO & Chief Reg. Affairs Officer
Vince Anicetti, COO
Erik Wiberg, VP, Corp. Dev. - Contact Info
-
Coherus BioSciences Inc.
Phone: (800) 794-5434
333 Twin Dolphin Dr., Ste. 600
Redwood City, CA 94065
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice